Dr. Lisa Carey

Medical oncologist and expert panel member at the University of North Carolina Lineberger Comprehensive Cancer Center, speaking about pembrolizumab use in early-stage triple-negative breast cancer and ASCO guideline updates.

Best podcasts with Dr. Lisa Carey

Ranked by the Snipd community

Apr 13, 2022 • 10min

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple Negative Breast Cancer Rapid Recommendation Update

Dr. Lisa Carey, a medical oncologist from the University of North Carolina Lineberger Comprehensive Cancer Center, sheds light on the recent updates regarding pembrolizumab for early-stage triple-negative breast cancer. She discusses the significance of the Keynote 522 trial and its implications for patient care. Additionally, she explains that PD-L1 testing is not necessary in these cases and shares insights on the broader practical applications of the guidelines. Dr. Carey also addresses outstanding questions regarding chemotherapy strategies and surgical considerations.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app